Why Waters Corporation (WAT) stock moved
Why Waters Corporation (WAT) rose 3.6% on November 18, 2026
Waters Corporation (WAT) rose 3.6% on November 18, 2026, closing at $466.10 versus $449.78 the prior session (close-to-close, from daily closes). The company is scheduled to present at the Evercore Healthcare Conference with CEO Udit Batra speaking, and Bridges Investment Management increased its WAT holdings by 170.6%, acquiring 5,845 shares to reach 9,272 total shares. Source: FMP price data; BestStocks detection.
Waters Corporation (WAT) moved +2.86% from $453.14 to $466.10 on 2026-11-18. The company is scheduled to present at the Evercore Healthcare Conference with CEO Udit Batra speaking, and Bridges Investment Management increased its WAT holdings by 170.6%, acquiring 5,845 shares to reach 9,272 total shares.
What to watch next: WAT earnings are scheduled for 2026-02-08 (consensus EPS estimate $4.63).
Earlier sessions that moved WAT
- +4.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −3.1%After reporting Q3 2026 results.
- −2.9%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −3.6%We checked news, earnings, analyst updates, filings, and corporate actions.
- +2.8%Analytical instruments sector ahead of upcoming earnings (per web search Oct 27).
- +3.3%Driven by strong sector momentum in life sciences tools and positive analyst momentum ahead of Q3 earnings on November 3.
- +3.5%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- −3.2%We checked news, earnings announcements, analyst updates, SEC filings, and corporate actions — no company-specific catalyst was found.
- +2.6%Driven by a confluence of positive catalysts: a UBS upgrade to Buy with a price target raised to $490 (per web_catalyst), the commercial global rollout of the BD FACSDiscover A7 Cell Analyzer for spectral flow cytometry (Yahoo Finance), and shareholder approval of the Reverse Morris Trust transaction combining Waters' analytical instruments business with Becton Dickinson's diagnostics and life sciences units.
Waters Corporation (WAT) shares rose 3.6% to $466.10 as of November 19, 2026, a moderate gain from the prior close of $449.78. BestStocks flagged the session as a major change for WAT. The move is tied to company news. Below, we break down what changed for WAT, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
WAT rose 3.6% in its latest session, moving from $449.78 to $466.10.
What it means for Waters Corporation investors
For Waters Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Positive 3.6% session move; Positive price momentum. Weighing against that: New SEC filing — review for material disclosures; New SEC filing — review for material disclosures. Wall Street's consensus price target sits at $470.00, implying +0.8% upside from $466.10. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality low (50/100). With earnings roughly 81 days out, the next report is the most likely near-term test of the move.
WAT price reaction
WAT last traded at $466.10, up $16.32 (+3.63%) from the previous close of $449.78. The session traded on 0.9× average volume (below avg), so participation was unremarkable. Over the past month the stock has ranged between $434.27 and $480.07, and it currently sits about 69% of the way up that band.
Bullish and bearish analyst opinions on Waters Corporation (WAT)
The consensus analyst price target on Waters Corporation (WAT) is $470.00, 0.8% above the recent $466.10. Over the past 90 days analysts logged 2 upgrades, 10 maintains, and 0 downgrades. Here is how the bullish and bearish cases on WAT line up.
The bullish case
- Wall Street's consensus price target of $470.00 implies +0.8% upside from $466.10.
- The Street's most bullish target is $535.00 (+14.8%).
- 2 analyst upgrades in the past 90 days, most recently UBS to Buy (2026-09-09).
- Positive 3.6% session move.
- Positive price momentum.
The bearish case
- The most bearish analyst target is $400.00 (-14.2%).
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 19, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for WAT
Frequently asked questions about WAT
Why did Waters Corporation (WAT) stock move?
Waters Corporation (WAT) rose 3.6% on November 18, 2026, closing at $466.10 versus $449.78 the prior session (close-to-close, from daily closes). The company is scheduled to present at the Evercore Healthcare Conference with CEO Udit Batra speaking, and Bridges Investment Management increased its WAT holdings by 170.6%, acquiring 5,845 shares to reach 9,272 total shares. Source: FMP price data; BestStocks detection.
How much did WAT stock rise?
WAT gained 3.63% ($16.32) versus the prior close of $449.78, last trading at $466.10 on 0.9× average volume.
When is Waters Corporation's next earnings date?
WAT's next earnings report is estimated for 2027-02-08 — about 81 days away.
What is the analyst price target for WAT?
The consensus analyst price target for WAT is $470.00, about 0.8% above the current $466.10. Over the past 90 days, analysts recorded 2 upgrades, 10 maintains, and 0 downgrades.
How BestStocks tracks WAT
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for WAT, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 19, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
